CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
CCTG is thrilled to welcome Lindsay Clarke, who will be supporting the Genitourinary Disease Site Committee as a Patient Representative.
Lindsay Clarke is a registered nurse and mother who lives in Fort Saskatchewan, Alberta. She has a passion for caring for others and she has been volunteering with Prostate Cancer Canada (Cancer Canada) for the last 14 years. Prostate cancer is common amongst the men in Lindsay’s family, she tragically lost her father to prostate cancer in 2010, he was only 58 years old.
Congratulations to Dr Michael Ong, who has received $2,487,015 over 7 years from the Canadian Institutes of Health Research (CIHR) to support the CCTG PR26 (TRIPLE-SWITCH) prostate clinical trial.
Plasma versus tissue tumor mutational burden as Biomarkers of Durvalumab plus Tremelimumab response in patients with metastatic colorectal cancer in the CO26 trial.
Jonathan M. Loree, Emma Titmuss, James T. Topham, Hagen F. Kennecke, Harriet Feilotter, Shakeel Virk, Young S. Lee, Kimberly Banks, Katie Quinn, Aly Karsan, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen
Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the CCTG LY12 clinical trial
The CEC6 trial, a Phase III intergroup study of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant pcv chemotherapy in patients with 1p/19q co-deleted anaplastic glioma or low-grade glioma, has closed to further accrual as the study has met the target sample size.
The New Investigator Clinical Trials Course (NICTC) is fast approaching and has already reached the maximum registration. The course will be held from August 21st to the 23rd at the Donald Gordon Hotel and Conference Centre in Kingston, Ontario.
NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of the course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
